



August 3, 2026

Company:	KYORIN Pharmaceutical Co., Ltd.
Representative:	Yutaka Ogihara Representative Director, President and CEO (Security Code: 4569, TSE Prime.)
Contact:	Shota Kikuchi Director, Corporate Planning
Telephone:	03-6374-9702

KYORIN to Commence Promotion Activities for Allergic Conjunctivitis Treatment Alesion® Eyelid Cream 0.5%

KYORIN Pharmaceutical Co., Ltd. announced today that it will commence promotion activities for Alesion® eyelid cream 0.5% (generic name: epinastine hydrochloride, hereinafter Alesion® Cream), a long-acting treatment for allergic conjunctivitis, effective August 17, 2026.

This initiative is based on the joint marketing agreement in Japan for Alesion® Cream, which was executed on July 13, 2026 with Santen Pharmaceutical Co., Ltd. (Head Office: Osaka City, Osaka; hereinafter Santen). Under the agreement, Santen will continue to be responsible for manufacturing, product distribution, and detailing for medical institutions specializing in the field of ophthalmology, with KYORIN handling detailing for medical institutions outside this field.

The two partners—KYORIN, with expertise in allergic diseases and a strong sales and marketing platform in the respiratory and otolaryngology fields, and Santen, a company specialized in ophthalmology, expect this joint marketing to enable them to deliver Alesion® Cream, a new treatment option for allergic conjunctivitis, to as many patients as possible, thereby contributing to improved patient quality of life (QOL).

If any matters arise that require timely disclosure regarding the impact of this matter on the consolidated earnings forecast for the fiscal year ending March 31, 2027, KYORIN will promptly announce them.

[Reference]

About Alesion® Cream 0.5%

Allergic conjunctivitis is typically treated with anti-allergy eye drops (mediator release inhibitors and histamine H1 receptor antagonists) which require application to the eye twice or four times a day. Alesion® Cream, which requires application only once daily to the periocular area (upper and lower eyelids), is the world's first cream treatment for allergic conjunctivitis. It was developed by Santen in the hope that this new formulation will eliminate the burden for patients to take their required dose, thereby improving patient adherence. Alesion® Cream's active ingredient is epinastine hydrochloride, a histamine H1 receptor antagonist which suppresses the release of chemical mediators from mast cells, making it an effective treatment option for the condition.

* Alesion® is a registered trademark of Boehringer Ingelheim KG.

About Santen

Santen is a global pharmaceutical company committed to advancing eye health and improving lives through better vision. Founded in 1890 in Osaka, Japan, Santen makes use of more than 135 years of experience in research and development, manufacturing, and marketing of pharmaceuticals and medical devices to help people around the globe maintain and improve their eye health. Santen focuses exclusively on eye health and its portfolio includes glaucoma, dry eye, infection, allergy, age-related macular degeneration, and myopia. Santen's products and services are available in more than 60 countries and regions. Guided by its Core Principle "Tenki ni sanyo suru" – Exploring the secrets and mechanisms of nature in order to contribute to people's health – Santen combines its expertise with deep patient focus to contribute to the realization of "Happiness with Vision."

For more information, please visit <https://www.santen.com/en>.

This document is for reference purposes only. In case of any discrepancy, the Japanese version shall prevail.